This Phase 1/2 clinical trial is investigating the safety and effectiveness of a targeted treatment combination using darovasertib (IDE196) and crizotinib in people with metastatic uveal melanoma. Darovasertib is a protein kinase C (PKC) inhibitor designed to target genetic pathways commonly involved in uveal melanoma, while crizotinib targets another pathway linked to tumour growth. Researchers hope the combination may help slow tumour growth and improve outcomes for patients with metastatic disease.
The study includes patients with metastatic uveal melanoma who have specific genetic mutations linked to the disease. Researchers are assessing the safest and most effective dose of the treatment combination, while also monitoring how well the drugs work together to shrink or control tumours. Participants receive the treatments orally and undergo regular scans, blood tests, and safety monitoring throughout the study.
Early results from the trial have shown encouraging tumour response and survival outcomes in some patients with metastatic uveal melanoma. However, this remains an investigational treatment and further research is needed to confirm its long-term benefits and safety.
At the present time, there are no active UK locations listed for this specific trial, and we are not currently aware of any plans for the study to open at UK sites